Скачать или смотреть Immunology Update Episode 5

🔬 Immunology Breakthroughs This Week! 🚀

Stay ahead with the latest immunology updates! From biosimilars and FDA approvals to game-changing clinical trial results, we cover the top innovations shaping autoimmune and inflammatory disease treatments.

🔥 This Week’s Top Stories:

💊 Fresenius Kabi Launches Otulfi, the 4th Stelara Biosimilar – A new ustekinumab biosimilar is now available for Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis.

🚀 FDA Approves Celltrion’s OMLYCLO, First Interchangeable Xolair Biosimilar – A major milestone in biologic accessibility for asthma and allergic diseases.

❌ Merck KGaA’s Lupus Trial Fails, but Company Pushes Forward – Despite missing primary endpoints, Merck continues developing enpatoran for lupus.

🧬 Agomab Reports Positive Phase 2a Interim Results for Crohn’s Disease Drug – A TGF-beta inhibitor shows strong efficacy in fibrostenosing Crohn’s disease.

🔬 Icotrokinra Shows Promising Results in Ulcerative Colitis Study – Johnson & Johnson’s icotrokinra (JNJ-2113) met its primary endpoint in a Phase 2b ulcerative colitis study, showing promising clinical response, remission rates, and sustained improvement with a well-tolerated, once-daily oral therapy

🏥 Arcutis Presents Phase 3 Data for Scalp & Body Psoriasis at AAD 2025 – Roflumilast cream demonstrates efficacy for psoriasis and atopic dermatitis.

🔍 New Analyses Explore Impact of SPEVIGO in Generalized Pustular Psoriasis – Post-hoc trial data highlights long-term treatment benefits.

🎯 BMS' Sotyktu Shows Superiority in Psoriatic Arthritis Phase 3 Trial – Deucravacitinib significantly improves joint and skin symptoms.

💉 Incyte’s Ruxolitinib Cream Delivers Positive Results for Prurigo Nodularis – TRuE-PN1 study reports significant itch reduction and skin clearance.

🧴 LEO Pharma Presents New Delgocitinib Cream Data for Chronic Hand Eczema – DELTA trials confirm deep and sustained responses in moderate-to-severe cases.

🌟 Eli Lilly’s EBGLYSS Maintains Clear Skin in Atopic Dermatitis Patients at 3 Years – Half of patients achieved completely clear skin with monthly injections.

🧪 Upadacitinib Demonstrates Biomarker-Driven Efficacy in Vitiligo – New data links treatment response to key inflammatory and melanocyte biomarkers.

📢 Stay Ahead in Immunology Research!
✅ Like, share, and subscribe for weekly updates on immunology and autoimmune diseases.
✅ Visit www.lqventures.com for expert healthcare insights and consulting services.
✅ Contact LucidQuest at [email protected] for strategic guidance on immunology innovations and clinical research.
🔔 Turn on notifications so you never miss an update!

#Immunology #AutoimmuneDiseases #Biosimilars #FDAApproval #ClinicalTrials #Biopharma #MedicalResearch #Dermatology #Psoriasis #IBD #LucidQuest